Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Single-Center Experience

Key Points

• Outcomes show significant improvement in hematologic recovery post-transplant, aiding patients with myelofibrosis.
• Key evidence indicates overall survival rates at 5 years reach 65% among recipients.
• Analysis from a single-center experience identifies risk factors affecting transplantation success.
• Highlights the importance of chimerism monitoring to predict and manage graft-versus-host disease risk.